Evidence supporting the use of: Docosahexaenoic Acid
For the health condition: Schizophrenia

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Docosahexaenoic acid (DHA), an omega-3 fatty acid, has been investigated for its potential role in the management of schizophrenia due to its importance in brain structure and function. Several studies have shown that individuals with schizophrenia often have lower levels of omega-3 fatty acids, including DHA, in their blood and brain tissues. Some randomized controlled trials (RCTs) and meta-analyses have explored whether supplementation with DHA (often combined with eicosapentaenoic acid, EPA) can improve symptoms of schizophrenia, particularly in early stages or in individuals at ultra-high risk for psychosis.

While a few studies have reported modest improvements in positive and negative symptoms, especially in patients with first-episode psychosis or those not yet on antipsychotic medications, the overall findings are inconsistent. Meta-analyses and systematic reviews generally conclude that omega-3 supplementation, including DHA, has limited efficacy as an adjunctive treatment for established schizophrenia, with small or nonsignificant effects on symptom severity. The evidence is stronger for possible preventive effects in high-risk individuals, but more research is needed. Guidelines do not universally recommend DHA for schizophrenia treatment, but ongoing research continues to explore its role.

In summary, there is a scientific rationale and some clinical research supporting the use of DHA for schizophrenia, but the evidence is weak to moderate and not conclusive. DHA is not considered a primary or standalone treatment for schizophrenia at this time.

More about Docosahexaenoic Acid
More about Schizophrenia

Products containing Docosahexaenoic Acid

We currently have no products on Vitabase that contain this ingredient.